Dunhill Financial’s TG Therapeutics TGTX Stock Holding History

Dunhill Financial’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$193	Hold	3	–	–	﹤0.01%	1267
2026 Q1	$116	Sell	3 -1	-25%	-$30	﹤0.01%	1371
2025 Q4	$105	Buy	+4	New	+$131	﹤0.01%	1372

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Dunhill Financial's TGTX Position: Q2 2026 in Review

Dunhill Financial held its TG Therapeutics (TGTX) position steady in Q2 2026 at 3 shares worth $193. The position accounts for ﹤0.01% of the portfolio, ranked #1267.

Dunhill Financial first reported a position in TGTX in Q4 2025 and has held it in 3 quarters since. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Dunhill Financial held 3 shares of TG Therapeutics worth $193 as of Q2 2026.
Dunhill Financial left its TG Therapeutics share count unchanged in Q2 2026.
TG Therapeutics made up ﹤0.01% of Dunhill Financial's portfolio in Q2 2026, its #1267 holding.
Dunhill Financial first reported a position in TG Therapeutics in Q4 2025 and has held it in 3 quarters since.
430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Dunhill Financial's 13F filing for Q2 2026, filed 7 Aug 2026.